Home News 24 key biopharmaceutical industry projects have been signed in Shanghai Lingang New Area

24 key biopharmaceutical industry projects have been signed in Shanghai Lingang New Area

by admin

Summary

[24 key biopharmaceutical industry key projects in Shanghai Lingang New Area are intensively signed]October 13th, Shanghai Lingang New Area held “Embracing Innovation, Taking Roots in Lingang”-2021 Shanghai International Biopharmaceutical Industry Week Lingang New Area Forum and biomedical concentration signing ceremony. At the signing ceremony, 24 key projects in the biomedical industry with a total investment of 14.7 billion yuan including Auscom, Cansino, Yixin Medical, Zhenge Biological, Jingfeng Medical, Smart One Technology, Shangyao Ruier, and WuXi Biologics were implemented. Lingang New Area. (China Securities Network)

October 13,Shanghai Lingang“Embracing innovation, taking root in Lingang” in the new area-2021 Shanghai International Biopharmaceutical Industry Week Lingang New Film Division Forum and Biomedicine Concentration Signing Ceremony. At the signing ceremony, Auscom, Cansino, Yixin Medical, Zhenge Biological, Jingfeng Medical, Huiyi Technology, Shangyao Ruier,WuXi Biologics24 key biomedical industry projects with a total investment of 14.7 billion yuan have landed in Lingang New Area.

The contracted project covers precision diagnosis, immunotherapy, gene therapy, high-end medical devices, vaccines, small molecule drug research and development, CRO/CDMO and other fields. It is a key point for the development of the biomedical industry in Lingang New Area. The “fast forward button”.

It is reported that since its establishment in August 2019, more than 80 projects in the biomedical industry in Lingang New Area have been implemented, with a total investment of about 41 billion yuan. The projects cover innovative biological drugs, key vaccines, high-end medical devices, CRO/CDMO services, etc. Multiple areas. In 2021, the total contracted investment exceeds 20 billion yuan, becoming an important growth pole of Shanghai’s biomedical industry, forming a leading position in quantity and a leading effect in quality.

See also  Fair compensation, ok from the third Commission to the Lega VdA proposal

(Source: China Securities Network)

.

0 comment
0

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy